Vascular Biogenics Ltd. (NASDAQ:VBLT) finished Wednesday with a subtraction of -$0.01 to close at $0.16, a downside of -7.07 percent. An average of 2,398,160 shares of common stock have been traded in the last five days. There was a fall of -$0.0569 in the past week, and it reached a new high 14 times over the past 12 months. The last 20 days have seen an average of 2,728,035 shares traded, while the 50-day average volume stands at 5,121,834.
VBLT stock has decreased by -27.48% in the last month. The company shares reached their 1-month lowest point of $0.1510 on 09/21/22. With the stock rallying to its 52-week high on 07/11/22, shares of the company touched a low of $0.16 and a high of $2.54 in 52 weeks. It has reached a new high 4 times so far this year and lost -92.12% or -$1.8148 in price. In spite of this, the price is down -93.89% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Vascular Biogenics Ltd. (VBLT) stock’s beta is 0.56. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 19.14, the price-to-book (PB) ratio at 0.35.
The quick ratio of Vascular Biogenics Ltd. for the three months ended June 29 was 4.10, and the current ratio was 4.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $0.4 million compared to revenue of $0.77 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Vascular Biogenics Ltd.’s return on assets was -62.40%.
For the three-month period that ended June 29, Vascular Biogenics Ltd. had $31.16 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $29.92 million in the quarter, while revenues were grew 19.02%. The analyst consensus anticipated Vascular Biogenics Ltd.’s latest quarter earnings to come in at -$0.1 per share, but it turned out to be -$0.12, a -20.00% surprise. For the quarter, EBITDA amounted to -$9.25 million.
From a technical analysis perspective, let’s take a brief look at Vascular Biogenics Ltd. (VBLT) price momentum. RSI 9-day as of the close on 21 September was 21.57%, suggesting the stock is oversold, with historical volatility in this time frame at 80.85%.
As of today, VBLT’s price is $0.1830 -26.83% or -$0.0569 from its 5-day moving average. VBLT is currently trading -26.27% lower than its 20-day SMA and -90.48% lower than its 100-day SMA. However, the stock’s current price level is -92.61% below the SMA50 and -92.75% below the SMA200.
The stochastic %K and %D were 8.49% and 11.59%, respectively, and the average true range (ATR) was 0.0186. With the 14-day stochastic at 5.60% and the average true range at 0.0268, the RSI (14) stands at 24.73%. The stock has reached -0.0222 on the 9-day MACD Oscillator while the 14-day reading was at -0.0273.
Oppenheimer downgraded Vascular Biogenics Ltd. (NASDAQ: VBLT) to a a Perform rating in its most recent analyst report. Previously, the stock was rated as an Outperform.